Azacitidine, venetoclax and G-CSF for newly diagnosed acute myeloid leukemia
Tests azacitidine, venetoclax and G-CSF combined in adults with newly diagnosed leukemia.
Plain-language title generated from the registry record
Registry title: Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
Key facts
- Where
- Huai'an, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with newly diagnosed acute myeloid leukemia (AML), not the APL type. They would take azacitidine, venetoclax and G-CSF together.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed AML, diagnosed by the 2022 WHO criteria. Acute promyelocytic leukemia (APL) is not included. ECOG performance status of 0-2. Expected survival of at least 3 months.
Main reasons for not taking part
- Acute promyelocytic leukemia (M3 subtype)
- Leukemia in the central nervous system
- Severe uncontrolled infection or other major diseases
- Heart failure (ejection fraction below 50%, NYHA class II or above)
- HIV positive, active hepatitis B or C, or pregnant or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06536010, who can take part
Where in China
- Huai'an Second People's HospitalHuai'an, ChinaContact: Xiaotian YangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yang Xiaotian
- Trial code
- NCT06536010
- Record updated
- 2 August 2024
- Original description
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML).Read full original descriptionShow less
Clinical Trial Protocol for the Combined Use of Azacitidine, Venetoclax, and Granulocyte Colony-Stimulating Factor in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase IIb, Single-arm, Prospective, Single-center Study)
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML).
The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to explore the synergistic mechanisms of VAG in combating AML.
Inclusion: Age between 18 and 75 years, regardless of gender; Diagnosis of AML (excluding APL) according to the 2022 World Health Organization (WHO) diagnostic criteria; ECOG performance status of 0-2; For female participants of childbearing potential or male participants with female partners of childbearing potential, effective contraceptive measures must be taken throughout the entire treatment period and for 6 months after the treatment period; Expected survival of at least 3 months; Ability to understand and willingness to participate in the study, and signing an informed consent form.
Exclusion: Severe uncontrolled infection or other major diseases; Human immunodeficiency virus (HIV) positive; Active hepatitis B or C; Other conditions in which the investigator deems the participant unsuitable for the study; Heart failure: Ejection fraction (EF) < 50%, New York Heart Association (NYHA) class II or above; Impaired liver or kidney function: Serum total bilirubin ≥ 2.0 mg/dl, AST ≥ 3 times the upper limit of normal, serum creatinine clearance rate (Ccr) ≥ 50 ml/min, arterial oxygen saturation (SpO2) < 92%; Acute promyelocytic leukemia (M3 subtype); Central nervous system leukemia; Pregnant or lactating women.